Beta Drugs Ltd.
NNSE:BETA1,971.00
INR
+306.30
(+18.40%)
ISIN
INE351Y01019
Return %
Stock
S&P 500
1Y
8.28
14.20
3Y
125.31
81.12
5Y
335.15
68.34
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.Company Description
- Full Time Employees
- 455
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Panchkula India
- IPO Date
- Oct 12, 2017
- Website
- betadrugslimited.com
- Similar Companies
- Business
- Beta Drugs Limited is an India-based pharmaceutical company that specializes in the development, manufacturing, and marketing of oncology formulations, active pharmaceutical ingredients (APIs), and specialized healthcare products. The company operates through a vertically integrated business model, delivering an extensive portfolio across various therapeutic areas: oncology finished dosage formulations, including cytotoxic oral solid dosages such as tablets and capsules, liquid injectables, lyophilized vials, and novel drug delivery system (NDDS) suspensions targeting breast, lung, ovarian, prostate, and hematological malignancies; branded proprietary pharmaceuticals, featuring key oncology brands such as ADLEAP (Enzalutamide), BEEDAN (Dasatinib), ADSUNIB (Sunitinib), GEM-RTU, ADLANTE, BEXINIB, and an in-house nanoparticle albumin-bound Paclitaxel; active pharmaceutical ingredients and cytotoxic intermediates, manufactured through its wholly owned subsidiary Adley Lab Limited to provide backward supply integration; general pharmaceutical injectables and supportive care therapies, produced via Adley Formulations Private Limited, covering immunosuppressants, antifungals, and cardiovascular medications; reproductive medicine and women's health treatments, developed through its majority-owned subsidiary Nivian Lifesciences Private Limited for in-vitro fertilization (IVF) and gynecological care; and contract development and manufacturing organization (CDMO) services for domestic and multinational pharmaceutical enterprises. Founded in 2005 and headquartered in Panchkula, Haryana, India, the company operates manufacturing facilities in Himachal Pradesh and Punjab, alongside an international production facility in Uzbekistan, distributing products across corporate hospitals, government healthcare institutions, and export destinations throughout the CIS region, Southeast Asia, Africa, and Latin America. In recent developments, Beta Drugs completed the strategic acquisition of a 66.09% controlling stake in Nivian Lifesciences for INR 69.4 crore to diversify into reproductive healthcare, secured new regulatory product registrations in Azerbaijan to expand its CIS market penetration, transitioned its equity listing to the Main Board of the National Stock Exchange of India, and expanded its sterile injectable and API manufacturing infrastructure to support growing international compliance and export demand.